Pamela Milani is the lead of MTGC. Dr. Milani is dedicated to advancing molecular technologies and their applications in research and clinical settings. Throughout her career, she has specialized in developing and validating genomic, transcriptomic and epigenomic methods based on Next Generation Sequencing (NGS), as well as non-NGS molecular assays such as quantitative polymerase chain reaction (qPCR)   and digital PCR. Before joining VRI, Dr. Milani led the genomic biomarker group at Bristol Myers Squibb (BMS), where she directed the adaptation, optimization and execution of genomic assays including multi-modal single cell sequencing, spatial transcriptomics and targeted NGS. She also developed multiplex digital PCR assays for variant detection and qPCR for oncovirus testing. Before BMS, she served as Senior Manager at Personalis, Inc., where she worked on launching novel genomic platforms for diagnostic applications and multidimensional biomarker identification. She completed her post-doctoral training in biological engineering at the Massachusetts Institute of Technology where she gained expertise in epigenomics, functional genomics and systems biology.